Stealth BioTherapeutics Announces “Path Forward” Despite Disappointing Delay for Ultra-rare Barth Syndrome

Following five years of discussions and a positive advisory committee recommendation, FDA proposes a potential accelerated approval pathway requiring resubmission of the elamipretide NDA Barth syndrome, a progressive, lethal, pediatric cardioskeletal disease often diagnosed at birth and…